Randomised Controlled Feasibility Trial
Cross-source consensus on Randomised Controlled Feasibility Trial from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Other
Other
Other
Highlighted claims
- The study was a single-centre, single-blinded randomised controlled feasibility trial in Switzerland conducted from May 2022 to May 2024. — Multimodal personalised executive function intervention (E-Fit) for school-aged children with complex congenital heart disease in Switzerland: a randomised controlled feasibility study
- Participants were randomised after baseline assessment to either E-Fit or a control group. — Multimodal personalised executive function intervention (E-Fit) for school-aged children with complex congenital heart disease in Switzerland: a randomised controlled feasibility study
- Outcomes were assessed at baseline, after 8 weeks, and at 4-month follow-up. — Multimodal personalised executive function intervention (E-Fit) for school-aged children with complex congenital heart disease in Switzerland: a randomised controlled feasibility study
- The study achieved an overall retention rate of 90%. — Multimodal personalised executive function intervention (E-Fit) for school-aged children with complex congenital heart disease in Switzerland: a randomised controlled feasibility study
- The trial enrolled 42 children after screening 60 participating patients for executive function problems. — Multimodal personalised executive function intervention (E-Fit) for school-aged children with complex congenital heart disease in Switzerland: a randomised controlled feasibility study